Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.
Elderly non-small cell lung cancer (NSCLC) patients undergoing definitive radiation have a lower incidence of esophagitis compared to younger patients and tolerate aggressive standard treatment regimens.
The Addario Lung Cancer Medical Institute, the Bonnie J. Addario Lung Cancer Foundation and Scancell Holdings PLC today announce a collaboration to evaluate the use of Scancell's second innovative cancer vaccine, SCIB2, from its ImmunoBody platform to treat non-small cell lung cancer.
Patients who experience anxiety and depression after being diagnosed with advanced lung cancer are more likely to die sooner, according to new research from the University of British Columbia and BC Cancer Agency.
Cancer is caused by an accumulation of genetic changes in a cell, that overcome the normal checks and balances leading to uncontrolled growth. A complex, interacting network of proteins controls all of a cell's processes, from metabolism to growth and division.
The discovery of several different subtypes of Non Small Cell Lung Cancer (NSCLC), the most frequent form of lung cancer, has been a major breakthrough in the fight against the leading cause of cancer-related death worldwide.
Non-small cell lung cancer patients with advanced disease receiving standard of care treatment have a higher overall survival than similar patients not receiving treatment.
Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that the widespread acquired resistance to immunotherapy drugs known as checkpoint inhibitors may be due to the elimination of certain genetic mutations needed to enable the immune system to recognize and attack malignant cells.
A new Yale study suggests that patients with a common form of lung cancer may still benefit from delayed chemotherapy started up to four months after surgery, according to the researchers.
A new study suggests patients who recover slowly from non-small-cell lung cancer (NSCLC) surgery may still benefit from delayed chemotherapy started up to four months after surgery, according to a new study published online by JAMA Oncology.
Fred Hutchinson Cancer Research Center announced its first-ever grants from its newly established Evergreen Fund to spur researchers' efforts to advance bold ideas toward creating or partnering with a commercial entity.
Early-stage non-small cell lung cancer (NSCLC) patients with squamous cell carcinoma (SqCC) have a significantly higher rate of local failure after stereotactic body radiation therapy (SBRT) than other NSCLC histological subtypes.
City of Hope patient Susan Young has had a remarkable response to a potentially revolutionary new treatment, a combination of the p53 cancer vaccine and a drug that blocks a specific cancer-aiding protein.
The biomarker PD-1, a protein, could potentially be used to predict survival or disease-free survival of lung cancer patients who have had the tumour surgically removed.
The ESMO Asia 2016 Congress announces its press programme today. The meeting brings together cancer experts in Singapore, from 16 to 19 December 2016.
Pembrolizumab was initially introduced for the treatment of melanoma. Since July 2016, the monoclonal antibody has also been available for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults whose tumours express the T-cell receptor ligand PD-L1 and who have received a prior chemotherapy regimen.
Immunotherapy continues to revolutionize the field of non-small cell lung cancer (NSCLC), with researchers now focusing on the optimal use of immune agents in the frontline setting.
The use of hybrid capture-based (HC-based) next-generation sequencing (NGS) to identify targetable oncogenic drivers in patients with lung adenocarcinoma results in the detection of genomic alterations (GAs) not identified in routine screening, and impacts treatment decisions and clinical outcomes.
Amgen and Allergan plc. today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 215, a biosimilar candidate to Avastin (bevacizumab).
Fred Hutchinson Cancer Research Center today announced the official opening of a first-of-its-kind clinic dedicated to providing innovative immunotherapies for cancer patients in clinical trials.
Pembrolizumab, an immunotherapy drug that was extensively evaluated by UCLA cancer researcher Dr. Edward Garon, has been approved by the U.S. Food & Drug Administration as first-line treatment for non-small cell lung cancer (NSCLC).